Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive multiple sclerosis (PPMS), revealing that it was at least as effective as its ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS). The ...

Compare Data Scientist vs Machine Learning Engineer roles in India 2026. Explore salary, skills, career paths, and find which ...

Google launches AI agent suite at Cloud Next 2026 with Workspace Studio, A2A protocol at 150 orgs, and Project Mariner. The pitch: only Google owns the full stack.